Study reveals eye pain as leading cause of outpatient and ED visits in US

News
Article

Estimating the number of such visits in the US may help guide research and clinical efforts to optimize outcomes, according to the researchers.

Emergency room clip board Image credit: AdobeStock/sudok1

Image credit: AdobeStock/sudok1

Investigators from the University of Michigan Medical School, Ann Arbor, reported that eye pain is the most frequent reason patients presented to ophthalmologists and emergency departments (EDs),1 according to first author Jeremy N. Shapiro, BA, from the Department of Ophthalmology and Visual Sciences.

The authors explained that estimating the number of such visits in the US may help guide research and clinical efforts to optimize outcomes.

Shapiro and his team conducted a retrospective cross-sectional study of data from the National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care Survey (2008-2019) to analyze a population-based sample of visits to outpatient clinics and EDs. The study included patients presenting with eye pain.

The data analysis showed that during the study period, there were 4.6 million outpatient and 1.0 million ED annual visits in which patients presented with eye pain visits.

More women than men presented to an outpatient visit (63.2%) and they were over 60 years of age (46.6%).

Men presented to the ED more often (51.8%)and they were younger than 45 years (aged <15 years, 16.4%; 15-24 years, 19.2%; and 25-44 years, 35.6%).

For almost half of the outpatient eye pain visits, the presenting complaint was considered nonacute. Eye pain was the primary reason for the visit in 42.0% of outpatient visits and 66.9% of ED visits, the authors reported. Eye pain was the only reason for the visit in 18.3% of outpatient and 32.7% of ED visits.

Ophthalmologists evaluated the largest number of outpatient visits (45.3%). The primary diagnoses were non–vision-threatening for most outpatient (78.5%) and ED (69.9%) visits when eye pain was the primary reason for the visit. The vast majority of patients (89.4%) in both settings had a follow-up visit scheduled.

Considering these results, the authors suggested, “Expanding therapeutic approaches to treat the causes of eye pain may reduce the burden on the health care system and optimize outcomes.”

Reference:
  1. Shapiro JN, Abuzaitoun RO, Pan Y, et al. Health care use for eye pain. JAMA Ophthalmol.2024;142:655-660. doi: 10.1001/jamaophthalmol.2024.1808
Recent Videos
Optometrists reflect on their residency experiences and provide advice to current residents.
In 2 weeks, the study participant's dry eye symptoms improved from 76 to 43 on a 0-100 rating scale, according to Marc-Matthias Schulze, PhD, Dipl Ing.
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.
Noreen Shaikh, OD, Magdalena Stec, OD, FAAO, and Brenda Bohnsack, MD, PhD, emphasize that collaboration and communication are key to proper diagnosis and treatment.
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
© 2024 MJH Life Sciences

All rights reserved.